Oxford Biomedica, AstraZeneca extend Covid vaccine deal
Oxford Biomedica said it had extended its agreement with AstraZeneca to mass-produce its Covid-19 vaccine candidate.
AstraZeneca
10,024.00p
17:15 19/11/24
1.10%
109.00p
FTSE 100
8,099.02
17:14 19/11/24
n/a
n/a
FTSE 250
20,427.62
16:34 19/11/24
n/a
n/a
FTSE 350
4,469.52
16:34 19/11/24
n/a
n/a
FTSE All-Share
4,427.06
16:59 19/11/24
n/a
n/a
Oxford Biomedica
412.50p
16:39 19/11/24
0.61%
2.50p
Pharmaceuticals & Biotechnology
19,328.21
16:34 19/11/24
0.64%
123.81
The company said AstraZeneca would give it $15m upfront to procure manufacturing capacity at its plant and that it could get an additional $35m plus other costs until the end of 2021 under the new 18-month deal.
AstraZeneca's vaccine candidate, known as AZD1222, has moved to late stage trials in the US. Oxford Biomedica said the deal announced on Tuesday could be further expanded by 18 months.